trending Market Intelligence /marketintelligence/en/news-insights/trending/v5kAXSxotGNYWyn0c5mmCg2 content esgSubNav
In This List

Inovio gets NIH grant to develop HIV immunotherapy

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Inovio gets NIH grant to develop HIV immunotherapy

National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a multiyear $7 million grant to Inovio Pharmaceuticals Inc. and its academic and industry collaborators for the development of a single or combination therapy using PENNVAX-GP with the goal of attaining long-term HIV remission in the absence of antiviral drugs.

The proof-of-concept clinical program will be a two-step clinical study testing the PENNVAX-GP and an immune activator alone and later on combined with a PD-1 checkpoint inhibitor. The study aims to examine whether enhancing anti-HIV specific CD8 killer T-cell immune responses alone or in combination with other products can influence the size of the viral reservoir pool, potentially resulting in reducing or eradicating the virus.

Inovio's PENNVAX-GP immunotherapy is undergoing a phase 1 trial evaluating its potential as a preventive vaccine.